{"database":"ENA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["Weinstock Lab, Medical Oncology, Dana-Farber Cancer Institute"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA261873"],"scientific_name":["Homo sapiens"],"long_description":["Gene expression profiling was performed to define transcriptional programs associated with response to type II JAK2 inhibitor NVP-CHZ868 alone or in combination with dexamethasone in vitro and in vivo. Overall design: MHH-CALL4 cells harboring a CRLF2 rearrangement and JAK2 I682F mutation were treated with vehicle, CHZ868, dexamethasone, or CHZ868 + dexamethasone combination for 12 hours in triplicate. RNA was then extracted for hybridization on Affymetrix microarrays. CRLF2+ patient-derived xenografts (05-412, 05-440, and 05-537) were treated in vivo for 3 days with vehicle, CHZ868, dexamethasone, or CHZ868 + dexmathasone combination for 3 days and then sacrificed. Transcriptional profiling was performed on unselected splenocytes from these animals."],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"Homo sapiens","description":"Type II JAK2 Inhibitor NVP-CHZ868 is Active in Vitro and in Vivo Against JAK2-Dependent B-cell Acute Lymphoblastic Leukemias","dates":{"last_updated":"2025-09-24","first_public":"2015-06-20"},"accession":"PRJNA261873","cross_references":{"GEO":["GSE61696"],"taxon":["9606"]}}